Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tara Helen Dowling"'
Autor:
Lars Herfindal, Fabrice Anizon, Stein Ove Døskeland, Pascale Moreau, Gro Gausdal, Tara Helen Dowling, Francis Giraud, Annette K. Brenner, Øystein Bruserud, Reidun Aesoy, Ronja Bjørnstad
Levels of Akt and p70 S6 kinase after treatment with Pim kinase inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b063659adab664bfac00b1c6a2c5b44
https://doi.org/10.1158/1535-7163.22506465.v1
https://doi.org/10.1158/1535-7163.22506465.v1
Autor:
Lars Herfindal, Fabrice Anizon, Stein Ove Døskeland, Pascale Moreau, Gro Gausdal, Tara Helen Dowling, Francis Giraud, Annette K. Brenner, Øystein Bruserud, Reidun Aesoy, Ronja Bjørnstad
Table showing inhibition of kinases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e531033ec943bd72887ea43f3ba7441
https://doi.org/10.1158/1535-7163.22506462.v1
https://doi.org/10.1158/1535-7163.22506462.v1
Autor:
Lars Herfindal, Fabrice Anizon, Stein Ove Døskeland, Pascale Moreau, Gro Gausdal, Tara Helen Dowling, Francis Giraud, Annette K. Brenner, Øystein Bruserud, Reidun Aesoy, Ronja Bjørnstad
More than 40 years ago, the present standard induction therapy for acute myeloid leukemia (AML) was developed. This consists of the metabolic inhibitor cytarabine (AraC) and the cytostatic topoisomerase 2 inhibitor daunorubucin (DNR). In light of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6bdfd6e8482005500d5231666572b03
https://doi.org/10.1158/1535-7163.c.6538410.v1
https://doi.org/10.1158/1535-7163.c.6538410.v1
Autor:
Atle Brendehaug, Riikka Karjalainen, Tara Helen Dowling, Stein-Erik Gullaksen, Caroline A. Heckman, Monica Hellesøy, Emmet McCormack, Øystein Bruserud, Eline Mejlænder-Andersen, Randi Hovland, Muntasir Mamun Majumder, Mihaela Popa, Samuli Eldfors, Bjørn Tore Gjertsen, Caroline Engen, Jonathan M. Irish, Kimmo Porkka, Brent Ferrell
SUMMARYAcute myeloid leukaemia (AML) is a highly heterogeneous disease. Here, we decipher the disease composition of a single AML patient through longitudinal sampling scrutinized by high-resolution genetic and phenotypic approaches, including sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9e217a2e82c99a265696b6e51262865
https://doi.org/10.1101/2020.11.03.20222885
https://doi.org/10.1101/2020.11.03.20222885
Autor:
Gro Gausdal, Reidun Aesoy, Pascale Moreau, Tara Helen Dowling, Øystein Bruserud, Ronja Bjørnstad, Lars Herfindal, Francis Giraud, Stein Ove Døskeland, Annette K. Brenner, Fabrice Anizon
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2019, 18 (3), pp.567-578. ⟨10.1158/1535-7163.MCT-17-1234⟩
Molecular Cancer Therapeutics, 2019, 18 (3), pp.567-578. ⟨10.1158/1535-7163.MCT-17-1234⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2019, 18 (3), pp.567-578. ⟨10.1158/1535-7163.MCT-17-1234⟩
Molecular Cancer Therapeutics, 2019, 18 (3), pp.567-578. ⟨10.1158/1535-7163.MCT-17-1234⟩
More than 40 years ago, the present standard induction therapy for acute myeloid leukemia (AML) was developed. This consists of the metabolic inhibitor cytarabine (AraC) and the cytostatic topoisomerase 2 inhibitor daunorubucin (DNR). In light of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5027f836fe595432255ec9fc180bce5
https://hal.archives-ouvertes.fr/hal-02151102
https://hal.archives-ouvertes.fr/hal-02151102
Autor:
Bjørn Tore Gjertsen, Geir Bredholt, Stein-Erik Gullaksen, Øystein Bruserud, Tara Helen Dowling Dowling Steinsland, Emmet McCormack, Mihaela Popa, Calum Leitch, Jostein Dahle, Mireia Mayoral Safont, Helen Heyerdahl, Astri Maaland
Publikováno v:
Blood. 136:26-26
Acute myeloid leukaemia is a disease of the haematopoietic stem and progenitor cells distinguished by an impairment of proliferation, propagation and differentiation of the haematopoietic lineage[1]. AML is a heterogenous disease, where patient strat
Autor:
Tara Helen Dowling, Frode Selheim, Carina Hinrichs, Rakel Brendsdal Forthun, Øystein Bruserud
Publikováno v:
Current pharmaceutical biotechnology. 17(1)
Acute myeloid leukemia (AML) is characterized as a heterogeneous disease where the patients are sub grouped according to several classification systems and mutational analyses. Diagnosis of AML is based on identification of the specific myeloid cell
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.